Abstract
6559 Background: Lapatinib, an oral small molecule dual tyrosine kinase inhibitor binds intracellularly to the ATP site of the EGFR and HER2 receptors. In EGF100151, L+C improved time to progression (TTP) and progression free survival (PFS) vs capecitabine alone (C- only) in women with HER2+ MBC who received prior therapy with TZ. Methods: We evaluated the CE (ΔCosts/ΔQuality Adjusted Life Years [QALYs]) of L+C vs C-only in women with HER2+ MBC who have received prior therapy with TZ from the UK NHS (National Health Service) perspective using an assumed acquisition cost and updated survival data (March 2007 EGF100151 data-cutoff). Because many patients in clinical practice receive monotherapy with vinorelbine (V-only) or TZ-only or combination therapy with TZ and C (TZ+C) or TZ and V (TZ+V), we also assessed the CE of L+C vs these treatment strategies. PFS and overall survival (OS) with L+C and C-only were based on Weibull survival functions estimated from data in EGF100151. Post-progression survival (PPS) for L+C and C-only were calculated as OS minus PFS. Since data from comparative trials in this population are lacking, PFS with TZ+C, TZ+V and TZ-only were estimated from published cohort studies of continued TZ±chemotherapy (TZ±CT) following progression; PPS was assumed to equal that of L+C. PFS and OS with V-only were assumed equal to that of C-only. Drug costs were from the British National Formulary; other costs were from NHS reference costs and published studies. Utility values for PFS were from EQ-5D data in EGF100151; for PPS, from a UK community-based preference study in MBC. Costs and QALYs were discounted at 3.5% annually. Results: L+C is dominant (provides more QALYs at a lower cost) vs TZ+V, TZ+C, and TZ-only. Conclusions: Using updated survival data from EGF100151 and indirect comparisons in the absence of head-to-head data, suggests that L+C is a cost effective therapy vs TZ±CT from the UK NHS perspective. L+C C-only V- only TZ+V TZ+C TZ-only Total costs (£) 26,489 12,745 15,034 30,997 28,906 27,619 Total QALYs 0.901 0.738 0.738 0.762 0.762 0.762 CE L+C vs (£/QALY) 83,999 70,011 dominant dominant dominant Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have